17/03/2019
Depression/Psychiatric Comorbidity Clinical Practice Guidelines (2019)
French Association for Biological Psychiatry and Neuropsychopharmacology and the Fondation FondaMental
February 26, 2019
*Comorbid Anxiety Disorders
First-intention medications and other treatment for MDD with comorbid obsessive-compulsive disorder, panic disorder, social anxiety, generalized anxiety disorder, or posttraumatic stress disorder include the following:
Selective serotonin reuptake inhibitor (SSRI)
Serotonin and norepinephrine reuptake inhibitor (SNRI)
Psychotherapy in combination
*Comorbid Substance Use Disorders
Full-time hospitalization or
Close monitoring in consultation (at least weekly)
Electrocardiographic evaluation prior to treatment
Substitution treatment initiated in response to opioid dependence
Also consider the following in first-intention treatment of patients with severe alcohol addiction:
Close biologic monitoring - Complete blood count, blood electrolytes, liver and renal function
Treatment of physical withdrawal syndrome
Antidepressant treatment - Prescribed after reassessment of mood and once appropriate care for physical withdrawal syndrome has ended
First-intention medications and other treatments for MDD with comorbid substance use disorders include the following:
Severe substance use disorders (except alcohol and ni****ne) - SSRI; SNRI; α2 antagonist; disease management involving a team specialized in addictology, psychoeducational groups, or psychotherapy focusing on addictive relapse prevention; concurrent treatment of MDD and addiction
Severe comorbid alcohol addiction - SSRI, SNRI, α2 antagonist, structured psychotherapy
Active smoking - SSRI, SNRI, α2 antagonist, structured psychotherapy, concurrent treatment of MDD and smoking cessation
*Comorbid Personality Disorders
First-intention treatment with SSRI or SNRI (as monotherapy or in combination with psychotherapy)
Second-intention treatment with an imipraminic antidepressant or α2 antagonist
*Geriatric Depressive Disorder
In adults over age 65 years, it is recommended, during an episode of MDD, that a physical examination and laboratory studies be performed to identify medical problems that could exacerbate or mimic depressive symptoms. Assessment includes the following:
Clinical examination
Biologic checkup - Ie, complete blood count, blood electrolytes, liver and renal function, and thyroid-stimulating hormone
Electrocardiographic evaluation
Mini-Mental State Examination
Evaluation of clinical severity using clinician- and self-rated scales
First-intention treatments for geriatric depression include the following:
Mild to moderate depression - SSRI, α2 antagonist
Moderate to severe depression - SSRI, SNRI, α2 antagonist
*Severe cognitive impairment - SSRI, SNRI
*Severe psychomotor agitation - SSRI, α2 antagonist
*Severe psychomotor retardation - SSRI, SNRI
*Severe sleep disorders - SSRI, α2 antagonist
*Severe anhedonia - SSRI, SNRI
*Psychotic symptoms - SNRI, potentiation with an atypical antipsychotic
*High su***de risk - SSRI, SNRI
For more information, WebMD or Medscape.
Cite this: Depression/Psychiatric Comorbidity Clinical Practice Guidelines (2019) - Medscape - Feb 26, 2019.